Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
- PMID: 20062090
- DOI: 10.1038/bmt.2009.360
Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
Abstract
Acute GVHD has remained a significant cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The role of TNF-alpha in the biology of acute GVHD after nonmyeloablative conditioning has not been studied thus far. Here, we measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-alpha in 106 patients before the start of the conditioning regimen (baseline) and 7 days after allogeneic HCT with nonmyeloablative conditioning. The nonmyeloablative regimen consisted of 2 Gy TBI alone (n=15), 2 Gy TBI plus fludarabine 90 mg/m2 (n=73), or 4 Gy TBI plus fludarabine 90 mg/m2 (n=18). TNFR1 levels increased significantly from baseline to day 7 after nonmyeloablative HCT (P<0.0001). Patients conditioned with 4 Gy TBI had higher TNFR1 day 7/baseline ratio than those conditioned with 2 Gy TBI (median 1.65 versus 1.25; P=0.01). In a multivariate Cox model, high TNFR1 day7/baseline ratio was associated with grades II-IV (HR=2.2, P=0.01) and grades III-IV (HR=2.9, P=0.007) acute GVHD, but had no impact on overall survival (P=0.8). In summary, our data suggest that nonmyeloablative conditioning induces the generation of TNF-alpha, and that the magnitude of TNF-alpha generation depends on the conditioning intensity (2 Gy versus 4 Gy TBI). Further, assessment of TNFR1 levels before and on day 7 after nonmyeloablative HCT provided useful information on subsequent risk of experiencing acute GVHD.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28. Biol Blood Marrow Transplant. 2010. PMID: 20109568 Clinical Trial.
-
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.Biol Blood Marrow Transplant. 2007 Jul;13(7):790-805. doi: 10.1016/j.bbmt.2007.03.002. Epub 2007 Apr 23. Biol Blood Marrow Transplant. 2007. PMID: 17580257
-
Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.Bone Marrow Transplant. 2010 Apr;45(4):689-93. doi: 10.1038/bmt.2009.230. Epub 2009 Aug 31. Bone Marrow Transplant. 2010. PMID: 19718063
-
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.Crit Rev Oncol Hematol. 2004 Sep;51(3):171-89. doi: 10.1016/j.critrevonc.2004.05.008. Crit Rev Oncol Hematol. 2004. PMID: 15331077 Review.
Cited by
-
Utilization of Clinical Data and Evaluation of Biomarkers in the Investigation of Graft-Versus-Host Disease Outcomes.Methods Mol Biol. 2025;2907:71-83. doi: 10.1007/978-1-0716-4430-0_3. Methods Mol Biol. 2025. PMID: 40100593
-
Advances in predicting acute GVHD.Br J Haematol. 2013 Feb;160(3):288-302. doi: 10.1111/bjh.12142. Epub 2012 Dec 4. Br J Haematol. 2013. PMID: 23205489 Free PMC article. Review.
-
The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.Biol Blood Marrow Transplant. 2016 Sep;22(9):1552-1564. doi: 10.1016/j.bbmt.2016.04.022. Epub 2016 May 5. Biol Blood Marrow Transplant. 2016. PMID: 27158050 Free PMC article.
-
Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis.Sci Rep. 2025 Jan 27;15(1):3364. doi: 10.1038/s41598-025-87801-2. Sci Rep. 2025. PMID: 39870810 Free PMC article.
-
Thinking out of the box--new approaches to controlling GVHD.Curr Hematol Malig Rep. 2014 Mar;9(1):73-84. doi: 10.1007/s11899-013-0187-9. Curr Hematol Malig Rep. 2014. PMID: 24390548 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical